VRN101099 not checked

Voronoi, Inc

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
HER2-positive Solid Tumors
Main trialPhase 1
“This Clinical trial is being done to understand how food and a common stomach-acid reducing medicine (called a proton pump inhibitor-PPI) affect how the body absorbs a new drug, VRN101099, in healthy adults. Researchers will measure how much of the drug gets into the bloodstream and how fast it gets there in each situation. This will help identify the most effective way for future patients to use VRN101099 in the treatment of solid tumors and cancers. The main questions it aims to answer is: 1. Does food or a PPI change how the body absorbs a single dose of VRN101099? 2. Is a single dose…”In the company’s words, NCT07550946 on ClinicalTrials.gov

Other drugs for HER2-positive Solid Tumors

All 397 drugs for HER2-positive Solid Tumors

Coming up1

Changes1

Last 90 days

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 1 Sep 2026 Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN101099 in Healthy Adult Participants
Phase 1Recruiting 1 Mar 2027 A Study of VRN101099 in Patients With HER2-Positive Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow VRN101099

Following is part of Solo: you see every change to VRN101099 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in